Stock Performance and Price Targets - BioMarin Pharmaceutical (BMRN) shares have gained 2.1% over the past four weeks, closing at $67.38 [1] - The mean price target estimate of $98.28 indicates a potential upside of 45.9% [1] - The average price target comprises 25 estimates ranging from $65 to $138, with a standard deviation of $17.42 [2] - The lowest estimate suggests a 3.5% decline, while the most optimistic estimate points to a 104.8% upside [2] Analyst Consensus and Earnings Estimates - Strong agreement among analysts about the company's ability to report better earnings strengthens the view of a potential upside [4] - The Zacks Consensus Estimate for the current year has increased 4.3% over the past month, with one positive revision and no negative revisions [10] - BMRN currently holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks [11] Analyst Behavior and Price Target Reliability - Analysts often set overly optimistic price targets to generate interest in companies with which their firms have business relationships [6] - A tight clustering of price targets, indicated by a low standard deviation, suggests a high degree of agreement among analysts [7] - Empirical research shows that price targets rarely indicate where a stock's price is actually heading [5] Investment Considerations - While price targets should not be entirely ignored, making investment decisions solely based on them could lead to disappointing returns [8] - The direction of price movement implied by the consensus price target appears to be a good guide, even if the target itself is not reliable [12]

SAN RAFAEL, Calif., Jan. 6, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will present at the 43rd Annual J.P. Morgan Conference on Monday, January 13, 2024, at 9:00 am PT / 12:00 pm ET, in San Francisco, California. An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available thro ...

Investors in BioMarin Pharmaceutical Inc. (BMRN) need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 17, 2025 $40 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It c ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores a ...

A month has gone by since the last earnings report for BioMarin Pharmaceutical (BMRN) . Shares have lost about 1.9% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is BioMarin due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Q3 Earnings & Sales Top EstimatesBioMarin r ...

BioMarin Pharmaceutical TodayBMRNBioMarin Pharmaceutical$63.44 +0.88 (+1.41%) 52-Week Range$61.15▼$99.56P/E Ratio37.99Price Target$94.20Add to WatchlistBioMarin Pharmaceutical NASDAQ: BMRN has been a rough investment for a long time. Over the past 10 years, shares have provided a total return of -28%. However, Wall Street analysts have consistently given this stock price targets that are much higher than its trading price. They see more fundamental value in the company than the market will give it credit f ...

Group 1 - The article discusses the investment opportunities in the biotech sector, particularly focusing on BioMarin and its hemophilia drug Roctavian, which is linked to the Prescription Drug User Fee Act (PDUFA) date [2] - The author emphasizes the importance of catalysts for both novice and experienced biotech investors, providing insights into product sales forecasts and integrated financial statements [2] - The article highlights the expertise of the author, who has over five years of experience in biotech consulting and has prepared detailed reports on more than 1,000 companies [2]

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market engagement and confidence [1][2] Zacks Style Scores - Zacks Style Scores are indicators that assist investors in selecting stocks likely to outperform the market within 30 days, rated from A to F based on value, growth, and momentum characteristics [3] - The Value Score focuses on identifying undervalued stocks using ratios like P/E, PEG, and Price/Sales [4] - The Growth Score emphasizes a company's financial health and future outlook, analyzing projected and historical earnings, sales, and cash flow [5] - The Momentum Score identifies optimal times to invest based on price trends and earnings estimate changes [6] - The VGM Score combines all three styles, providing a comprehensive rating based on value, growth, and momentum [7] Zacks Rank - The Zacks Rank is a proprietary model that leverages earnings estimate revisions to guide investors in portfolio creation [8] - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [9] - There are over 800 stocks rated 1 or 2, which can be overwhelming for investors [10] Investment Strategy - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [11] - Stocks with a 3 (Hold) rank should also have A or B Scores to ensure potential upside [11] - The direction of earnings estimate revisions is crucial; stocks with lower ranks and declining forecasts pose higher risks [12][13] Company Spotlight: BioMarin Pharmaceutical (BMRN) - BioMarin Pharmaceutical Inc. specializes in developing treatments for severe medical conditions, primarily in children [14] - BMRN holds a 3 (Hold) Zacks Rank and a VGM Score of A, with a Value Style Score of B, indicating attractive valuation metrics such as a forward P/E ratio of 19.13 [15] - Recent analyst revisions have increased earnings estimates for fiscal 2024, with the Zacks Consensus Estimate rising by $0.02 to $3.27 per share, alongside an average earnings surprise of 28.7% [15] - With a solid Zacks Rank and strong Value and VGM Style Scores, BMRN is recommended for investors' consideration [16]

Group 1 - BioMarin Pharmaceutical Inc. will present at three upcoming investor conferences, including the UBS Global Healthcare Conference, Jefferies London Healthcare Conference, and the Evercore ISI HealthCONx Conference [2][1] - An audio webcast of the presentations will be available live and archived on the company's website for a limited time [2][3] - BioMarin is a global biotechnology company focused on developing medicines for rare genetic conditions, with a strong pipeline and eight commercial therapies [3]

Core Insights - Zacks Premium provides tools for investors to enhance their stock market strategies and confidence [1] - The Zacks Style Scores serve as complementary indicators to the Zacks Rank, aiding in stock selection [2] Zacks Style Scores Overview - Stocks are rated from A to F based on value, growth, and momentum qualities, with A indicating the highest potential for outperformance [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score [3][4][5] Value Score - Focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [3] Growth Score - Concentrates on a company's financial health and future growth potential, analyzing projected and historical earnings, sales, and cash flow [4] Momentum Score - Targets stocks with upward or downward price trends, utilizing metrics like one-week price change and monthly earnings estimate changes [4] VGM Score - Combines all three Style Scores to identify stocks with the best value, growth forecasts, and momentum [5] Zacks Rank Integration - The Zacks Rank is a proprietary model based on earnings estimate revisions, which helps investors build successful portfolios [6] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +25.41%, significantly outperforming the S&P 500 [7] Stock Selection Strategy - Investors should prioritize stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal success [8] - Stocks with lower ranks but high Style Scores may still carry risks due to downward earnings outlooks [9] Company Spotlight: BioMarin Pharmaceutical (BMRN) - BioMarin focuses on developing treatments for severe medical conditions, particularly in children, and currently holds a 3 (Hold) Zacks Rank with a VGM Score of A [10] - The company has a forward P/E ratio of 20.18, indicating attractive valuation metrics for value investors [10] - Recent analyst revisions have increased the earnings estimate for fiscal 2024 to $3.27 per share, with an average earnings surprise of 28.7% [11]